Format

Send to

Choose Destination
Eur J Haematol. 2016 Jun;96(6):564-77. doi: 10.1111/ejh.12749. Epub 2016 Mar 9.

A practical review on carfilzomib in multiple myeloma.

Author information

1
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
2
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.
3
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Abstract

Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.

KEYWORDS:

carfilzomib; combination regimen; induction; multiple myeloma; proteasome inhibitors; relapse

PMID:
26893241
DOI:
10.1111/ejh.12749
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center